Cleary JF: Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain. Seminars in Oncology. 1997; 24(S): S13-S19.
2.
Pappagallo M, Dickerson ED, Hulka S: Palliative care and hospice opioid dosing guidelines with breakthrough pain (BP) doses. American Journal of Hospice & Palliative Care. November/December 2000; 17(6): 407-413.
3.
Farrar JT, Cleary J, Rauck R, et al.: Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. Journal of the National Cancer Institute. 1998; 90: 611-616.
4.
Christie JM, Simmonds M, Patt R, et al.: Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. Journal of Clinical Oncology. 1998; 16: 3238-3245.
